Background: Definition of benign multiple sclerosis (BMS) remains controversial. Moreover, a sizeable proportion of classically defined BMS patients may be no longer benign (NLB) when re-assessed in the long-term. In a previous work, we found that after a five-year follow-up, a clinical score was able to identify patients at risk of losing their benign status. Objectives: In this 12-year reappraisal of the same cohort, we aimed at assessing the predictive value of the same score in the long-term. Methods: After a mean follow-up of 12.6 + 0.4 years, patients still having an EDSS score <3.0 were classified as “still benign” (SB), whereas patients having an EDSS score ≥3.5 were defined as NLB. The predictive value of the mentioned score was re-assessed using survival analysis. Results: By the end of the follow-up, 20 (32.8%) were classified as NLB. Patients were grouped on the basis of the above mentioned score. Patients with score 2–3 were at higher risk of NLB status at the follow-up (HR = 3.5; 95%CI 1.5–8.6; p = 0.005, accuracy = 70.5%). Conclusions: In patients with established BMS, prognostic prediction of longer-term disease course remains of critical value. In this study, a clinical score was able to predict disease evolution in the long term.
Razzolini, L., Portaccio, E., Stromillo, M.L., Goretti, B., Niccolai, C., Pastò, L., et al. (2018). The dilemma of benign multiple sclerosis: Can we predict the risk of losing the “benign status”? A 12-year follow-up study. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 26, 71-73 [10.1016/j.msard.2018.08.011].
The dilemma of benign multiple sclerosis: Can we predict the risk of losing the “benign status”? A 12-year follow-up study
Stromillo, Maria Laura;Battaglini, Marco;Giorgio, Antonio;De Stefano, Nicola;Amato, Maria Pia
2018-01-01
Abstract
Background: Definition of benign multiple sclerosis (BMS) remains controversial. Moreover, a sizeable proportion of classically defined BMS patients may be no longer benign (NLB) when re-assessed in the long-term. In a previous work, we found that after a five-year follow-up, a clinical score was able to identify patients at risk of losing their benign status. Objectives: In this 12-year reappraisal of the same cohort, we aimed at assessing the predictive value of the same score in the long-term. Methods: After a mean follow-up of 12.6 + 0.4 years, patients still having an EDSS score <3.0 were classified as “still benign” (SB), whereas patients having an EDSS score ≥3.5 were defined as NLB. The predictive value of the mentioned score was re-assessed using survival analysis. Results: By the end of the follow-up, 20 (32.8%) were classified as NLB. Patients were grouped on the basis of the above mentioned score. Patients with score 2–3 were at higher risk of NLB status at the follow-up (HR = 3.5; 95%CI 1.5–8.6; p = 0.005, accuracy = 70.5%). Conclusions: In patients with established BMS, prognostic prediction of longer-term disease course remains of critical value. In this study, a clinical score was able to predict disease evolution in the long term.File | Dimensione | Formato | |
---|---|---|---|
322.pdf
non disponibili
Descrizione: The dilemma of benign multiple sclerosis: Can we predict the risk of losing the
Tipologia:
PDF editoriale
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
282.48 kB
Formato
Adobe PDF
|
282.48 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1071768